1. Radivoyevitch T, Jankovic GM, Tiu RV, Saunthararajah Y, Jackson RC, Hlatky LR, et al. Sex differences in the incidence of chronic myeloid leukemia. Radiat Environ Biophys. 2014; 53(1): 55-63.
2. Druker BJ. Translation of the Philadelphia chromosome into therapy for CML. Blood. 2008; 112(13): 4808-17.
3. Antoszewska-Smith J, Pawlowska E, Blasiak J. Reactive oxygen species in BCR-ABL1-expressing cells - relevance to chronic myeloid leukemia. Acta Biochim Pol. 2017; 64(1): 1-10.
4. Nguyen H, Syed V. Progesterone inhibits growth and induces apoptosis in cancer cells through modulation of reactive oxygen species. Gynecol Endocrinol. 2011; 27(10): 830-6.
5. Zhang C, Sheng J, Li G, Zhao L, Wang Y, Yang W, et al. Effects of Berberine and Its Derivatives on Cancer: A Systems Pharmacology Review. Front Pharmacol. 2019; 10: 1461.
6. Habtemariam S. Recent Advances in Berberine Inspired Anticancer Approaches: From Drug Combination to Novel Formulation Technology and Derivatization. Molecules. 2020; 25(6).
7. Tong L, Chuang CC, Wu S, Zuo L. Reactive oxygen species in redox cancer therapy. Cancer Lett. 2015; 367(1): 18-25.
8. Zou Z, Chang H, Li H, Wang S. Induction of reactive oxygen species: an emerging approach for cancer therapy. Apoptosis. 2017; 22(11): 1321-35.
9. Pascu VEG, AM GA. Assessment of Oxidative Stress in Patients with Chronic Myeloid Leukemia Depending on Associated Comorbidities. Curr Health Sci J. 2020; 46(1): 23-30. DOI: 10.12865/CHSJ.46.01.04
10. Fink M. Possible effect of medroxyprogesterone acetate (MPA) in lymphoid blast crisis of chronic myelogenous leukemia. Ann Hematol. 1994; 68(2): 89-90.
11. Achi IT, Sarbadhikary P, George BP, Abrahamse H. Multi-Target Potential of Berberine as an Antineoplastic and Antimetastatic Agent: A Special Focus on Lung Cancer Treatment. Cells. 2022; 11(21): 3433.
12. Wassmann K, Wassmann S, Nickenig G. Progesterone antagonizes the vasoprotective effect of estrogen on antioxidant enzyme expression and function. Circ Res. 2005; 97(10): 1046-54.
13. Wang Y, Liu Y, Du X, Ma H, Yao J. The Anti-Cancer Mechanisms of Berberine: A Review. Cancer Manag Res. 2020; 12: 695-702.
14. Li Z, Jiang T, Lu Q, Xu K, He J, Xie L, et al. Berberine attenuated the cytotoxicity induced by t-BHP via inhibiting oxidative stress and mitochondria dysfunction in PC-12 cells. Cell Mol Neurobiol. 2020: 40(4): 587-602.
15. Zhang R, Qiao H, Chen S, Chen X, Dou K, Wei L, et al. Berberine reverses lapatinib resistance of HER2-positive breast cancer cells by increasing the level of ROS. Cancer Biol Ther. 2016; 17(9): 925-34.
16. Radivoyevitch T, Jankovic GM, Tiu RV, Saunthararajah Y, Jackson RC, Hlatky LR, et al. Sex differences in the incidence of chronic myeloid leukemia. Radiat Environ Biophys. 2014; 53(1): 55-63.
17. Druker BJ. Translation of the Philadelphia chromosome into therapy for CML. Blood. 2008; 112(13): 4808-17.
18. Antoszewska-Smith J, Pawlowska E, Blasiak J. Reactive oxygen species in BCR-ABL1-expressing cells - relevance to chronic myeloid leukemia. Acta Biochim Pol. 2017; 64(1): 1-10.
19. Nguyen H, Syed V. Progesterone inhibits growth and induces apoptosis in cancer cells through modulation of reactive oxygen species. Gynecol Endocrinol. 2011; 27(10): 830-6.
20. Zhang C, Sheng J, Li G, Zhao L, Wang Y, Yang W, et al. Effects of Berberine and Its Derivatives on Cancer: A Systems Pharmacology Review. Front Pharmacol. 2019; 10: 1461.
21. Habtemariam S. Recent Advances in Berberine Inspired Anticancer Approaches: From Drug Combination to Novel Formulation Technology and Derivatization. Molecules. 2020; 25(6).
22. Tong L, Chuang CC, Wu S, Zuo L. Reactive oxygen species in redox cancer therapy. Cancer Lett. 2015; 367(1): 18-25.
23. Zou Z, Chang H, Li H, Wang S. Induction of reactive oxygen species: an emerging approach for cancer therapy. Apoptosis. 2017; 22(11): 1321-35.
24. Pascu VEG, AM GA. Assessment of Oxidative Stress in Patients with Chronic Myeloid Leukemia Depending on Associated Comorbidities. Curr Health Sci J. 2020; 46(1): 23-30. DOI: 10.12865/CHSJ.46.01.04
25. Fink M. Possible effect of medroxyprogesterone acetate (MPA) in lymphoid blast crisis of chronic myelogenous leukemia. Ann Hematol. 1994; 68(2): 89-90.
26. Achi IT, Sarbadhikary P, George BP, Abrahamse H. Multi-Target Potential of Berberine as an Antineoplastic and Antimetastatic Agent: A Special Focus on Lung Cancer Treatment. Cells. 2022; 11(21): 3433.
27. Wassmann K, Wassmann S, Nickenig G. Progesterone antagonizes the vasoprotective effect of estrogen on antioxidant enzyme expression and function. Circ Res. 2005; 97(10): 1046-54.
28. Wang Y, Liu Y, Du X, Ma H, Yao J. The Anti-Cancer Mechanisms of Berberine: A Review. Cancer Manag Res. 2020; 12: 695-702.
29. Li Z, Jiang T, Lu Q, Xu K, He J, Xie L, et al. Berberine attenuated the cytotoxicity induced by t-BHP via inhibiting oxidative stress and mitochondria dysfunction in PC-12 cells. Cell Mol Neurobiol. 2020: 40(4): 587-602.
30. Zhang R, Qiao H, Chen S, Chen X, Dou K, Wei L, et al. Berberine reverses lapatinib resistance of HER2-positive breast cancer cells by increasing the level of ROS. Cancer Biol Ther. 2016; 17(9): 925-34.